EU approves Avastin for lung cancer

August 24, 2007

The European Union has approved the anti-cancer drug Avastin as a first-line treatment for advanced lung cancer.

European officials said the drug, which is already approved in the United States, can be used as a first-line treatment for patients with advanced non-small cell lung cancer in combination with platinum-based chemotherapy.

Swiss drug maker Roche said Avastin is the only first-line therapy to demonstrate improved survival benefits beyond one year in patients with advanced lung cancer, the company said Friday in a release.

Roche said Avastin is the first treatment that inhibits angiogenesis, which is the growth of a network of blood vessels that supply nutrients and oxygen to cancerous tissues.

Avastin targets a naturally occurring protein called VEGF (Vascular Endothelial Growth Factor), a key mediator of angiogenesis, thus choking off the blood supply that is essential for the growth of the tumor and its spread throughout the body

The drug is also used in the treatment of breast, colorectal and kidney cancers.

Copyright 2007 by United Press International

Explore further: US panel rejects Avastin for breast cancer use

Related Stories

US panel rejects Avastin for breast cancer use

June 29, 2011

An expert panel urged the US Food and Drug Administration on Wednesday to strip the Roche-made drug Avastin of its label for use against breast cancer because it is neither safe nor effective.

FDA panel: Revoke drug's breast cancer approval

June 28, 2011

(AP) -- A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the government to remove its ...

Hearing may be end of road for breast cancer drug

June 27, 2011

(AP) -- The best-selling cancer drug in the world comes under federal scrutiny once again this week, as drugmaker Roche makes a last-ditch effort to keep Avastin approved for breast cancer, despite evidence that it is ineffective ...

Analysis details Avastin's rare fatal side effects

February 1, 2011

(AP) -- A new analysis raises fresh questions about the risks of the blockbuster cancer drug Avastin, suggesting the chance of dying from side effects linked to it is higher than the risk for patients on chemotherapy alone.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.